Abstract:Background: The optimal timing for initiation of antiretroviral therapy (ART) in HIV-positive patients with cryptococcal meningitis (CM) has not, as yet, been compellingly elucidated, as research data concerning mortality risk and the occurrence of immune reconstitution inflammatory syndrome (IRIS) in this population remains inconsistent and controversial. Method: The present multicenter randomized clinical trial was conducted in China in patients who presented with confirmed HIV/CM, and who were ART-naïve. Subjects were randomized and stratified into either an early-ART group (ART initiated 2–5 weeks after initiation of antifungal therapy), or a deferred-ART group (ART initiated 5 weeks after initiation of antifungal therapy). Intention-to-treat, and per-protocol analyses of data for these groups were conducted for this study. Result: The probability of survival was found to not be statistically different between patients who started ART between 2–5 weeks of CM therapy initiation (14/47, 29.8%) vs. those initiating ART until 5 weeks after CM therapy initiation (10/55, 18.2%) ( p = 0.144). However, initiating ART within 4 weeks after the diagnosis and antifungal treatment of CM resulted in a higher mortality compared with deferring ART initiation until 6 weeks ( p = 0.042). The incidence of IRIS did not differ significantly between the early-ART group and the deferred-ART group (6.4 and 7.3%, respectively; p = 0.872). The percentage of patients with severe (grade 3 or 4) adverse events was high in both treatment arms (55.3% in the early-ART group and 41.8% in the deferred-ART group; p =0.183), and there were significantly more grade 4 adverse events in the early-ART group (20 vs. 13; p = 0.042). Conclusion: Although ART initiation from 2 to 5 weeks after initiation of antifungal therapy was not significantly associated with high cumulative mortality or IRIS event rates in HIV/CM patients compared with ART initiation 5 weeks after initiation of antifungal therapy, we found that initiating ART within 4 weeks after CM antifungal treatment resulted in a higher mortality compared with deferring ART initiation until 6 weeks. In addition, we observed that there were significantly more grade 4 adverse events in the early-ART group. Our results support the deferred initiation of ART in HIV-associated CM. Clinical Trials Registration: www.ClinicalTrials.gov , identifier: ChiCTR1900021195.

Failure of Early Mycological Clearance in HIV-Negative Cryptococcal Meningitis

Unique Clinical Features of Cryptococcal Meningitis among Chinese Patients Without Predisposing Diseases Against Patients with Predisposing Diseases

Unique Cerebrospinal Fluid Profiles of Patients With Human Immunodeficiency Virus- Associated Cryptococcal Meningitis With a Ventriculoperitoneal Shunt : A Retrospective Cohort Study

Importance Of Fibrosis 4 Index Score And Mode Of Anti-Fungal Treatment To The Outcome Of Cryptococcal Meningitis In Hepatitis B Virus-Infected Patients

Short-Course Rather Than Low-Dose Amphotericin B May Exert Potential Influence on Mortality in Cryptococcal Meningitis Patients Treated with Amphotericin B Plus Flucytosine Alone or in Combination with Fluconazole

HIV Infection Does Not Increase 10-Week Mortality of Chinese Cryptococcal Meningitis Patients

Analysis of the Relationship Between Drug Susceptibility of Cryptococcus Neoformans Isolates and Mortality in HIV-negative Cryptococcal Meningitis

AAIT: A Novel Prognostic Model for HIV-negative Patients with Cryptococcal Meningoencephalitis New Scoring Model for Non-HIV Patients with CM

A 12-Year Single-Center Experience in China

Clinical Features and Outcomes of Cryptococcemia Patients with and Without HIV Infection

Factors Associated with Mortality in Cryptococcal Meningitis

Cerebrospinal Fluid Lactate Levels as a Prognostic Indicator in Patients With Cryptococcal Meningitis Who Are HIV Negative: A Retrospective Cohort Study

Clinical Characteristics, Treatment, and Outcome of Low-Risk Non-Hiv-associated Cryptococcal Meningitis: A Retrospective Cohort Study.

Cerebrospinal Fluid Microscopy As An Index For Predicting The Prognosis Of Cryptococcal Meningitis Patients With And Without Hiv

A retrospective research of HIV-negative cryptococcal meningoencephalitis patients with acute/subacute onset

Clinical characteristics and prognostic factors of 60 patients with acquired immune deficiency syndrome combined with Cryptococcus neoformans

A Comparison of the Clinical Characteristics and Outcomes of Cryptococcal Meningitis in HIV-negative Individuals with and Without Immunosuppression

Clinical Features and Treatment Outcomes of Human Immunodeficiency Virus-Associated Cryptococcal Meningitis: a 2-Year Retrospective Analysis

Cryptococcal Meningitis in Non-Hiv-infected Patients in a Chinese Tertiary Care Hospital, 1997-2007.

Cryptococcal meningitis: Diagnosis and treatment

The Effect of Early vs. Deferred Antiretroviral Therapy Initiation in HIV-Infected Patients With Cryptococcal Meningitis: A Multicenter Prospective Randomized Controlled Analysis in China